Pfizer and Sanofi have each made multi-billion-dollar purchases that widen the scope of their pipelines. Pfizer’s $43 billion acquisition of antibody–drug conjugate (ADC) specialist Seagen gives Pfizer access to Seagen’s linkers, a key part of the technology, and Sanofi’s $2.9 billion buyout of Provention Bio gives Sanofi control of the recently approved Tzield (teplizumab), the first disease-modifying drug for type 1 diabetes (T1D).
Access options
Subscribe to this journal
Receive 12 print issues and online access
214,86 € per year
only 17,91 € per issue
Rent or buy this article
Get just this article for as long as you need it
$39.95
Prices may be subject to local taxes which are calculated during checkout
About this article
Cite this article
Biotech mega-deals boost Pfizer, Sanofi pipelines.
Nat Biotechnol 41, 439 (2023). https://doi.org/10.1038/s41587-023-01761-4
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41587-023-01761-4
